Phenobarbital administered alone or in combination with dapsone inhibits apoptosis and improves motor function after spinal cord injury in rats
DOI:
https://doi.org/10.31157/an.v20i4.98Keywords:
spinal cord injury, phenobarbital, dapsone, neuroprotection.Abstract
Traumatic spinal cord injury (SCI) is a health problem that affects the working age population (20-45 years) and there is no effective treatment. Our group has demonstrated that phenobarbital (FB) and dapsone (DDS) have neuroprotective effects in models of stroke and excitotoxicity. Objective: to evaluate the therapeutic effect of FB administered alone or in combination with DDS during the acute stage after SCI by measuring the activity of Caspase3 and motor functional recovery. Material and methods: female rats (250 g) were used, the groups were: laminectomy (control), SCI, treated with FB or DDS, alone or in combination, and all them sacrificed 72 h after surgery to measure the activity of caspase-3, motor recovery was evaluated for 2 months. Results: the values of caspase-3 activities showed an increase by effect of lesion and were diminished in all animals that received treatments administered alone or in combination. Likewise, animals treated with FB alone or in combination with DDS had the best functional performance, being the most effective the combined therapy with an increase of 135% over the lesion group. Conclusions: the results obtained demonstrated that both drugs provide therapeutic benefits by reducing apoptosis and promoting functional recovery of the animals. Therefore, the findings of this study may have value as an effective pharmacological strategy in clinical practice.Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2015 Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez
This work is licensed under a Creative Commons Attribution 4.0 International License.
September 2022-present © Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Open access articles under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. No commercial re-use is allowed.
January-September 2022 © The authors. Open access articles under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. No commercial re-use is allowed.
January 2014-December 2021 © Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Open access articles under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.